Loading stock data…
Beam Therapeutics Inc (BEAM)
$34.95+0.14 (+0.40%)
After Hours$34.98+0.03 (+0.09%)· Last close Jun 29
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Beam Therapeutics Inc. in the Healthcare sector is trading at $34.95 with a market capitalization of $3.1B. Wall Street consensus targets $51.07 (15 analysts), implying a +46.1% move over the next 12 months. The stock is currently near its 52-week high of $36.88, remaining 27.4% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +46.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $31.74M↓ | $114.11M↑ | $9.70M↑ | $8.47M↑ | $7.47M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$107.22M↓ | -$17.45M↑ | -$126.81M↓ | -$120.15M↓ | -$119.29M |
| Net Income | -$94.32M↓ | $244.30M↑ | -$112.73M↓ | -$102.29M↑ | -$108.33M |
Peer Comparison
JNJUNHPFE
Fundamentals
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogen...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.13B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-5.59%
Volume
Today's trading volume
2.89M
Recent News
Tesla’s 10% Weight in ARKK Sets Up a Make-or-Break Year for the Innovation ETF
The ARK Innovation ETF (NYSEARCA:ARKK) has barely moved this year, gaining about 2% year to date through late June and sitting at roughly $78 per share. That stasis hides a violent tug of war inside the portfolio: AMD has more than doubled, up 144% YTD, while Coinbase has shed 34% and Tesla (NASDAQ:TSLA), ARKK’s largest ... Tesla’s 10% Weight in ARKK Sets Up a Make-or-Break Year for the Innovation ETF
BEAM Stock Gains 5% as FDA Clears BEAM-304 IND for Phenylketonuria
Beam Therapeutics gains after the FDA clears the IND for BEAM-304 in PKU, advancing its liver-targeted gene-editing program into clinical testing.
Is Beam Therapeutics Inc. (BEAM) One of the Best Genomics Stocks to Buy According to Analysts?
Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the 8 Best Genomics Stocks to Buy According to Analysts. On May 18, 2026, Beam Therapeutics Inc. (NASDAQ:BEAM) presented updated Phase 1/2 data for BEAM-302 in alpha-1 antitrypsin deficiency at the American Thoracic Society International Conference. The firm detailed safety, durability, and reduced neutrophil elastase activity following treatment. […]
Beam Therapeutics Stock Soars 21% in Three Months: Here's Why
BEAM shares jump 21% in three months as promising BEAM-302 data, pipeline milestones and a cash runway into mid-2029 boost investor confidence.
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026
Genomics and synthetic biology are reshaping healthcare, with growing demand for precision medicine spotlighting stocks like PACB, MYGN and TWST.